Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2022-06-08
DOI
10.1016/j.annonc.2022.05.518
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The management of metastatic GIST: current standard and investigational therapeutics
- (2021) Ciara M. Kelly et al. Journal of Hematology & Oncology
- Thermodynamic Dissection of Potency and Selectivity of Cytosolic Hsp90 Inhibitors
- (2021) Chihoko Yoshimura et al. JOURNAL OF MEDICINAL CHEMISTRY
- Design of placebo-controlled randomized trials of anticancer agents: Ethical considerations based on a review of published trials
- (2021) Adélaïde Doussau et al. Clinical Trials
- Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2020) Jean-Yves Blay et al. LANCET ONCOLOGY
- First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors
- (2019) Akihiko Shimomura et al. MOLECULAR CANCER THERAPEUTICS
- Secondary KIT mutations: the GIST of drug resistance and sensitivity
- (2019) Andrea Napolitano et al. BRITISH JOURNAL OF CANCER
- Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial
- (2019) Toshihiko Doi et al. EUROPEAN JOURNAL OF CANCER
- TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours
- (2019) Yurina Saito et al. BRITISH JOURNAL OF CANCER
- Translational insights into gastrointestinal stromal tumor and current clinical advances
- (2018) M L Hemming et al. ANNALS OF ONCOLOGY
- Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies
- (2016) Kjetil Søreide et al. Cancer Epidemiology
- Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma
- (2015) Ruth Seggewiss-Bernhardt et al. CANCER
- TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90 and , Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models
- (2014) S. Ohkubo et al. MOLECULAR CANCER THERAPEUTICS
- Methods for Adjusting for Bias Due to Crossover in Oncology Trials
- (2014) K. Jack Ishak et al. PHARMACOECONOMICS
- Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial
- (2013) Yoon-Koo Kang et al. LANCET ONCOLOGY
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) George D Demetri et al. LANCET
- The HSP90 Inhibitor, AT13387, Is Effective against Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor Models
- (2012) T. Smyth et al. MOLECULAR CANCER THERAPEUTICS
- Heat shock protein 90 inhibition: rationale and clinical potential
- (2012) Robert B. Den et al. Therapeutic Advances in Medical Oncology
- Heterogeneity of kinase inhibitor resistance mechanisms in GIST
- (2008) B Liegl et al. JOURNAL OF PATHOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search